	US 12,233,136 B2
	Myosin 15 promoters and uses thereof
Joseph Burns, Newton, MA (US); Kathryn Ellis, Arlington, MA (US); Adam Palermo, Somerville, MA (US); Martin Schwander, Auburndale, MA (US); and Jonathon Whitton, Cambridge, MA (US)
Assigned to Decibel Therapeutics, Inc., Boston, MA (US)
Appl. No. 17/050,741
Filed by Decibel Therapeutics, Inc., Boston, MA (US)
PCT Filed Apr. 26, 2019, PCT No. PCT/US2019/029366 § 371(c)(1), (2) Date Oct. 26, 2020, PCT Pub. No. WO2019/210181, PCT Pub. Date Oct. 31, 2019.
Claims priority of provisional application 62/663,679, filed on Apr. 27, 2018.
Prior Publication US 2021/0236654 A1, Aug. 5, 2021
Int. Cl. A61K 48/00 (2006.01); A61P 27/16 (2006.01); C07K 14/47 (2006.01)

CPC A61K 48/0058 (2013.01) [A61P 27/16 (2018.01); C07K 14/4716 (2013.01); C12N 2750/14143 (2013.01)]

25 Claims

1. A polynucleotide comprising a first region having at least 85% sequence identity to SEQ ID NO: 1 or a functional portion thereof comprising the sequence of SEQ ID NO: 3 and/or SEQ ID NO: 4, operably linked to a second region having at least 85% sequence identity to SEQ ID NO: 2 or a functional portion thereof comprising the sequence of SEQ ID NO: 8 and/or SEQ ID NO: 9, wherein the first region is fused directly to the second region or is joined to the second region by a linker comprising one to one hundred nucleotides.